Mavorixafor Patent Expiration
Mavorixafor was first introduced by X4 Pharmaceuticals Inc
Mavorixafor Patents
Given below is the list of patents protecting Mavorixafor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xolremdi | US10548889 | Compositions of CXCR4 inhibitors and methods of preparation and use | Dec 11, 2038 | X4 Pharms |
| Xolremdi | US11045461 | Compositions of CXCR4 inhibitors and methods of preparation and use | Dec 11, 2038 | X4 Pharms |
| Xolremdi | US12115156 | Compositions of CXCR4 inhibitors and methods of preparation and use | Dec 11, 2038 | X4 Pharms |
| Xolremdi | US10610527 | Methods for treating immunodeficiency disease | Dec 22, 2036 | X4 Pharms |
| Xolremdi | US11219621 | Methods for treating immunodeficiency disease | Dec 22, 2036 | X4 Pharms |
| Xolremdi | US10953003 | Methods for treating cancer | Dec 14, 2036 | X4 Pharms |
Mavorixafor's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Mavorixafor:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | X4 Pharmaceuticals | NA |
RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome | X4 Pharmaceuticals | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | X4 Pharmaceuticals | NA |
COMPLETED
(Jul 1, 2026)
| PHASE1 |